In Vitro Diagnostics Quality Control Market Growth at 5.5% CAGR to Reach USD 3.01 Bn by 2032

Key Highlights

• The In Vitro Diagnostics Quality Control Market was valued at USD 2.07 Bn in 2025.
• Revenue is expected to reach USD 3.01 Bn by 2032.
• The market is projected to grow at a 5.5% CAGR during 2026–2032.
• Quality Control Products led the product and service segment in 2025.
• Clinical Chemistry and Immunochemistry were the most widely used technologies in 2025.
• Molecular Diagnostics is emerging as the fastest-growing technology segment.
• Clinical Laboratories dominated the end-user segment in 2025.
• North America led the market; Asia Pacific is expected to grow fastest.
• 24.5 million HIV patients globally received antiretroviral medication in 2019.

Why This Matters Now

Diagnostic volume is rising faster than laboratory tolerance for error. Hospitals, clinical laboratories and IVD manufacturers now need quality control systems that protect patient results, reimbursement access and regulatory standing together.

In Vitro Diagnostics Quality Control Market move from USD 2.07 Bn in 2025 to USD 3.01 Bn by 2032 signals a controlled but critical spending cycle. QC is now a patient-safety, compliance and throughput asset.

Market Overview

In Vitro Diagnostics Quality Control covers samples and materials used to verify IVD testing-system reliability. These controls help ensure test accuracy and evaluate how environmental conditions and operator performance affect results.

Demand is rising because infectious diseases, HIV, malignancies, diabetes, cardiovascular diseases and other chronic conditions are increasing diagnostic volumes. UNAIDS data cited by MMR states that 24.5 million HIV patients globally received antiretroviral medication in 2019. That treatment base requires reliable diagnostic monitoring.

Clinical laboratories are also facing tighter certification requirements. CLIA-accredited laboratories are eligible for Medicare and Medicaid payments, making quality compliance directly tied to revenue access.

Request for sample copy of this report: https://www.maximizemarketresearch.com/request-sample/161874/

Key Trends Driving Growth

Authorized clinical laboratories are expanding worldwide. COVID-19 increased diagnostic testing demand, and government agencies established additional laboratories to raise testing capacity. This widened the need for QC systems that can handle higher sample volumes.

Laboratory accreditation is becoming more formal. ISO 15189:2012 and similar standards are increasingly required across countries. Several European countries require certification for numerous laboratory tests.

Multi-analyte controls are changing laboratory economics. MMR states that laboratories previously had to keep more than thirty unique controls, but now can use one or two multi-analyte controls to support reliable testing. That cuts QC time and simplifies inventory.

Regulatory complexity remains a restraint. FDA expectations for 510(k) notifications have increased, raising data and documentation demands for IVD producers.

Segment Insights

• Dominant Segment: Quality Control Products. Quality Control Products led the product and service segment in 2025 because laboratories rely on control materials and third-party QC to meet regulatory requirements.
• Fastest-Growing Segment: Molecular Diagnostics. Molecular Diagnostics is emerging as the fastest-growing technology segment, driven by genetic testing, infectious disease detection and personalized medicine.
• Dominant Technology Signal: Clinical Chemistry and Immunochemistry. These were the most widely used technologies in 2025 because they support routine metabolic, hormone and infectious disease testing.
• Dominant End User: Clinical Laboratories. Clinical Laboratories dominated in 2025 because they conduct large volumes of diagnostic tests daily.
• Other Segments: Data Management Solutions, Quality Assurance Services, Microbiology, Hematology, Coagulation/Hemostasis, Hospitals, Academic and Research Institutes, Home-care and Other End Users. Exact shares are not disclosed.
• Digital QC Signal: Data Management Solutions. Adoption is increasing as laboratories automate reporting and improve regulatory compliance.

Regional Growth Story

North America led the global market in 2025. The region benefits from advanced healthcare infrastructure, strong regulatory standards and high adoption of automated diagnostic technologies. Thermo Fisher Scientific, Abbott Laboratories and Bio-Rad Laboratories strengthen the regional supplier base.

Europe held the second-largest share. Strict laboratory quality regulations and broad quality assurance programs support demand. The UK, France and Germany are included in the regional scope, but country-level revenue figures are not disclosed.

Asia Pacific is expected to experience the fastest growth. China, India and Japan are highlighted because healthcare infrastructure is expanding, diagnostic volumes are rising and laboratories are investing in modernization.

Competitive Landscape

The market includes QC material suppliers, diagnostics companies, instrument manufacturers, third-party control producers and laboratory software providers. Key players include Bio-Rad Laboratories, Randox Laboratories, Thermo Fisher Scientific, LGC, Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher, Sysmex, Ortho-Clinical Diagnostics, Quidel, Seegene, Bio-Techne, Microbix Biosystems, Streck and Grifols.

Competition is moving toward platform-based QC. Companies that combine control materials, peer-comparison software, EQA programs and data management can serve high-throughput laboratories better than single-product suppliers.

Bio-Rad’s software launch shows the direction. Randox’s EQA program shows maternal-health biomarkers are becoming a quality-control priority. Revvity’s NGS and ddPCR standards signal demand for precision diagnostics support.

Request for sample copy of this report: https://www.maximizemarketresearch.com/request-sample/161874/

Recent Developments

• bioMérieux announced commercial expansion of GENE-UP PRO HRM on 11 March 2026. The DNA-based molecular test for heat-resistant molds reduces diagnostic-error risk in microbiology.
• Independent and commercial laboratories reached a significant growth milestone on 23 February 2026. Automated multi-analyte QC platforms support high-throughput compliance.
• Randox Laboratories launched a RIQAS External Quality Assessment program for pre-eclampsia testing on 01 July 2025. The program improves maternal-health biomarker standardization.
• Revvity introduced three Mimix reference standards for NGS and ddPCR IVD applications on 15 June 2025. The FDA-aligned standards reduce assay variability for complex somatic mutations.
• Roche launched a CE-marked Chest Pain Triage algorithm on 28 April 2025. The IVD device combines high-sensitivity troponin assays with algorithmic quality controls.
• Bio-Rad launched Unity Next Peer QC software on 14 January 2025. The platform enables real-time peer comparison and centralized reporting.

Strategic Implications

For hospitals, QC systems protect patient outcomes and reimbursement pathways. Poor quality control can delay diagnosis, repeat testing and weaken clinical confidence.

For clinical laboratories, multi-analyte controls reduce operational complexity. Data management tools also improve audit readiness.

For IVD manufacturers, regulatory expectations are increasing. Stronger data packages and compliant labeling are now competitive requirements.

For investors, the market rewards tools that reduce laboratory error while improving throughput. Molecular diagnostics, software-based QC and third-party controls offer the clearest leverage.

Future Outlook

The In Vitro Diagnostics Quality Control Market is positioned for steady expansion as infectious disease testing, chronic disease monitoring, molecular diagnostics, clinical laboratory certification and data-driven QC increase demand. North America leads through regulation and automation, while Asia Pacific offers the fastest growth through laboratory modernization and rising diagnostic volume.

Future leaders will combine control materials, digital QC, regulatory readiness and molecular-diagnostic standards, while laggards will remain exposed to laboratory error, compliance delays and low-margin commodity controls.

Related Reports

Drug Screening Market: https://www.maximizemarketresearch.com/market-report/global-drug-screening-market/1352/

Animal Model Market: https://www.maximizemarketresearch.com/market-report/animal-model-market/221562/

Global Foot and Mouth Disease Vaccines Market: https://www.maximizemarketresearch.com/market-report/foot-and-mouth-disease-vaccines-market/122248/

Analyst Perspective

“According to Komal Patil, Research Analyst at Maximize Market Research, ‘The In Vitro Diagnostics Quality Control Market is projected to grow from USD 2.07 Bn in 2025 to USD 3.01 Bn by 2032 at a 5.5% CAGR, supported by rising diagnostic testing, infectious disease burden, chronic disease monitoring, laboratory certification and molecular diagnostics. Quality Control Products lead the visible product structure, while Molecular Diagnostics is emerging as the fastest-growing technology segment. Providers that integrate control materials with digital quality systems will be better positioned.’”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com